Top Injectable Manufacturer in Comoros – Reliable Pharmaceutical Solutions
Last Updated: September 11, 2026
TL;DR: The Comorian rulebook is eight days old. On 3 September 2026 ANAMEV published, for the first time in one place, eleven CTD dossier checklists, the marketing-authorisation form and five governing decisions. A decision is due within 90 days — but the clock starts when fees are paid, and the fee schedule is published nowhere. The commercial route is narrower still: the national list of licensed wholesalers has exactly one entry.
Key Takeaways
ANAMEV published its complete marketing-authorisation requirements on 3 September 2026. Any guidance on Comorian registration written before that date describes a different regime.
Décision N°012 adopts mutual recognition and the WHO Collaborative Registration Procedure — then names no authority at all, and CDSCO appears nowhere. WHO prequalification of the active ingredient is the one mechanism that measurably shortens the dossier.
OCOPHARMA is the only licensed wholesaler in the country, serving 25 licensed pharmacies across three islands. Representing your products requires a pharmacien-conseil resident in the Comoros who is jointly liable alongside you.
Today the control that actually binds is customs, not registration: a per-consignment import licence cleared in four working days, then physical inspection that names injectable medicines as its own category.
Introduction: What an Injectable Manufacturer in Comoros Has to Prove
Every market in this series opens with the same question — does the country name the foreign regulators whose decisions it will lean on, and is India's CDSCO among them? The Union of the Comoros answers in a way no earlier market has, because its answer is eight days old. On 3 September 2026 the Agence Nationale des Médicaments et des Évacuations Sanitaires published eleven CTD dossier checklists, the marketing-authorisation form and five governing décisions. Before that, the regime existed only on paper under the 2020 Code de la Santé Publique.
Read what it says rather than what it suggests. Article 10 of Décision N°012 adopts the principle of mutual recognition and implements the WHO Collaborative Registration Procedure — and then names no authority. There is no reliance list and no mention of CDSCO anywhere in ANAMEV's published set. What is named is narrower and more useful to a manufacturer: a country-of-origin marketing authorisation or a WHO-format Certificate of a Pharmaceutical Product, a WHO-format GMP certificate, bioequivalence data, and a French-language summary of product characteristics on the WHO model. The only pharmacopoeia named anywhere is the European one.
What Sets a World-Class Injectable Manufacturer in Comoros Apart
The one place the new rulebook offers genuine leverage is WHO prequalification. Where the active ingredient is WHO-prequalified, parts of Module III fall away: container-closure data is not required, and manufacturing information is required only where finished-product sterility depends on the active ingredient. That is the closest thing to an abridged pathway in the Comorian system, and it is earned in a laboratory rather than negotiated in a meeting.
Against that sits an arithmetic problem worth stating plainly. Article 11 gives ANAMEV a maximum of 90 days to grant or refuse a new authorisation — but the clock starts on the date the fees are paid, and we could find no published fee schedule to pay against. The file must also pass the Commission Nationale d'Homologation des Produits Pharmaceutiques and a technical expert committee, each of which ordinarily meets once a quarter. A 90-day maximum gated behind two quarterly calendars is a planning constraint, and a supplier who offers a firm date should be asked how they arrived at it.
Quality Systems Behind Every Sterile Injectable We Ship to Comoros
The dossier ANAMEV now asks for is largely the dossier a serious sterile plant already generates. Farbe Firma manufactures under WHO-GMP certification in ISO Class 5 filling environments, with validated aseptic process simulation, environmental monitoring and container-closure integrity testing. Release testing runs on HPLC and GC against USP, BP, IP or EP monographs, with LAL for bacterial endotoxins and Karl Fischer for moisture in lyophilised vials. Stability follows ICH Q1A with Q1B photostability, on the climatic zone an equatorial island destination actually requires.
Two Comoros-specific details change how the file is assembled. The summary of product characteristics must be in French and follow the WHO model — a translation workstream to be scheduled, not an afterthought at submission. And the generic route requires bioequivalence or comparative dissolution data as a matter of course. Dossiers are built in CTD structure, with ACTD available where a regulator prefers it; we found no Comorian requirement for eCTD and therefore claim none.
Working out whether Comoros is reachable for your product? Talk to our regulatory team
Why Farbe Firma is the Trusted Injectable Manufacturer in Comoros for Global Buyers
Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than 30 countries. For Comoros we can build the CTD dossier, supply the WHO-format CPP and GMP certificate, generate bioequivalence and stability data, and prepare the French RCP. What we cannot do is import. ANAMEV's published list of licensed wholesalers contains exactly one entry — the state-owned OCOPHARMA in Moroni — against 25 licensed pharmacies in the whole country. We hold no Comorian registration and recommend no partner we have not verified.
Representation is regulated separately and more heavily than most exporters expect. Under Décision N°007, a medical promotion or representation agency must retain a pharmacien-conseil who resides in the Comoros and is registered with the Ordre National des Pharmaciens, and that pharmacien-conseil is jointly liable, criminally included, alongside the agency. The commercial gate is tighter than the technical one. And for the malaria, HIV and tuberculosis volumes that dominate donor spending, a second gate sits above both: the Global Fund's quality-assurance policy accepts WHO prequalification, a pre-2015 stringent regulatory authority, a WHO Listed Authority, or its Expert Review Panel — and India's CDSCO is none of those for medicines, since WHO lists it at maturity level 3 for vaccines only.
The numbers are small and the honesty about them matters more than the size. Population was 866,628 in 2024 on World Bank figures; current health expenditure was 6.55% of GDP in 2023, with 56.57% paid out of pocket and 26.77% financed externally, on WHO Global Health Expenditure Database data. That external share was 43.30% a year earlier — households, not donors, absorbed the swing. We will not print a market-size figure: the two mirror-trade sources we found differ by roughly five times. Nor will we print a registration fee, because none is published. One caveat we would rather state than hide: OCOPHARMA's own quality lead listed non-registration among the system's live gaps in 2024, and WHO's 2024–2028 country strategy records essential-medicine availability at 28%.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Does Comoros recognise India's CDSCO or Indian regulatory approval?
We found no Comorian instrument naming CDSCO, and no published list of recognised foreign regulators. Décision N°012 adopts mutual recognition as a principle and implements the WHO Collaborative Registration Procedure, but names no authority to recognise. What ANAMEV does require is a country-of-origin marketing authorisation or a WHO-format Certificate of a Pharmaceutical Product, plus a WHO-format GMP certificate — requirements about document format, not about which agency issued the approval.
Is the Indian Pharmacopoeia accepted in Comoros?
Not as far as any published document shows. The only pharmacopoeia named in ANAMEV's dossier requirements is the European Pharmacopoeia, through a certificate of suitability. Specifying to an Indian Pharmacopoeia monograph is not prohibited and may be entirely appropriate for the molecule — but nothing in the Comorian rulebook gives it recognised status, and a supplier claiming otherwise is reading something that is not there.
Does a foreign manufacturer need a local partner in Comoros?
Effectively yes, on two counts. Importing requires an establishment registered with ANAMEV holding a one-year import approval, and ANAMEV's published wholesaler list has a single entry. Separately, promoting or representing your products requires a ministerially authorised agency retaining a pharmacien-conseil resident in the Comoros and registered with the Ordre National des Pharmaciens, who carries joint liability. Neither route lets an overseas manufacturer act alone.
What does registration cost in Comoros, and how long does it take?
We will print a timeline and not a cost. Décision N°012 sets a maximum of 90 days for a decision on a new application and on a renewal, with renewals filed at least three months before expiry. But the 90 days run from the date fees are paid, and we could find no published fee schedule — the amounts are set by decisions of ANAMEV's Director-General that are not on the public record. Confirm both with ANAMEV directly.
What actually controls an injectable consignment arriving in Comoros today?
Customs, in practice. Every import needs a prior ANAMEV licence requested through the SYDONIAWorld system, with a published processing time of four working days and a fee of 10,000 KMF. On arrival a separate release authorisation applies: documentary inspection within 48 working hours, then physical inspection at the port or airport, under procedures that name injectable medicines as their own inspection category. Thermolabile and biological products can move under a provisional release.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments